Richard Klausner resigned from the Gates Foundation, saying move was unrelated to Congressional investigation of NCI contract to Harvard University during Klausner’s tenure as NCI director.
FDA’s Oncologic Drugs Advisory Committee recommended approval of three drugs for cancer, voted down one.
Three cancer centers joined the Multiple Myeloma Research Consortium.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Alec Kimmelman named director of Perlmutter Cancer Center, quickly replacing ousted Benjamin Neel
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State